AstraZeneca's Calquence Steps Up in First-Line CLL
Full Results Of First-Line Calquence Use In CLL
A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.
You may also be interested in...
Shifting EU Treatment Paradigms In CLL
The CLL market segment in the EU will now include a first-line combination therapy of AbbVie’s venetoclax and Roche’s obinutuzumab, which has recently been approved by the European Commission.
Seven Talking Points At ASH 2019
The tireless pace of change in hemato-oncology was showcased in Orlando.
Merck & Co. Joins Competitive BTK Research Space With $2.7bn ArQule Buy
ArQule's lead candidate, ARQ 531, is a novel BTK inhibitor in Phase II development that could work in patients with B-cell malignancies resistant to existing BTK inhibitors like Imbruvica.